Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Eli Lilly and Co LLY on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and Wegovy — a shift that could raise costs for patients.

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Shares of telehealth company Hims & Hers skyrocketed Monday after the company struck a deal with Danish drugmaker Novo Nordisk to sell its GLP-1 weight-loss medications, ending the feud between the ...

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could ...

Hers is currently offering 20% off GLP-1 medication for eligible subscribers who pay over $500 for weight-loss services.

Eli Lilly warns compounded tirzepatide mixed with B12 may contain impurities and safety risks as FDA tightens GLP-1 rules—get the latest updates now.

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular weight-loss drugs like Ozempic and Zepbound.

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

A Kentucky lawmaker has filed a new bill that would strengthen oversight of compounded drugs, including weight loss medication.